Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Whitehawk Therapeutics (WHWK) over the last 4 years, with Q1 2025 value amounting to $760000.0.

  • Whitehawk Therapeutics' Cost of Revenue rose 1656.44% to $760000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 5096.49%. This contributed to the annual value of $3.0 million for FY2024, which is 765.4% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Cost of Revenue stood at $760000.0 for Q1 2025, which was up 1656.44% from $790000.0 recorded in Q4 2024.
  • Whitehawk Therapeutics' 5-year Cost of Revenue high stood at $927000.0 for Q4 2023, and its period low was $179000.0 during Q1 2022.
  • Its 4-year average for Cost of Revenue is $609846.2, with a median of $656000.0 in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 31756.76% in 2023, then tumbled by 1477.89% in 2024.
  • Quarter analysis of 4 years shows Whitehawk Therapeutics' Cost of Revenue stood at $222000.0 in 2022, then soared by 317.57% to $927000.0 in 2023, then dropped by 14.78% to $790000.0 in 2024, then decreased by 3.8% to $760000.0 in 2025.
  • Its Cost of Revenue stands at $760000.0 for Q1 2025, versus $790000.0 for Q4 2024 and $804000.0 for Q3 2024.